{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:14:29Z","timestamp":1778501669409,"version":"3.51.4"},"reference-count":37,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Project of the Yunnan Province Agricultural Basic Research Joint Foundation","award":["202401BD070001-056"],"award-info":[{"award-number":["202401BD070001-056"]}]},{"name":"Yunnan Key Research and Development Project","award":["202503AS090008"],"award-info":[{"award-number":["202503AS090008"]}]},{"name":"Project of Yunnan International Science and Technology Specialists","award":["202403AK140041"],"award-info":[{"award-number":["202403AK140041"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Background: Acquired resistance to the third-generation EGFR tyrosine kinase inhibitor osimertinib, often mediated by EGFR triple mutations, poses a major clinical challenge in non-small cell lung cancer (NSCLC) treatment. Among these, some rare mutations, such as L858R\/T790M\/L792H and L858R\/T790M\/G796R, create steric hindrance that directly interferes with osimertinib binding, yet effective targeted therapeutic strategies for these specific mutations remain lacking. Cudratricusxanthone A (CTXA), a natural xanthone derivative isolated from Cudrania tricuspidata Bur., has demonstrated various pharmacological activities, but its effects against EGFR triple-mutant NSCLC have not been systematically investigated. Methods: Stable Ba\/F3 and NIH\/3T3 cell lines expressing EGFR L858R\/T790M\/L792H or L858R\/T790M\/G796R triple mutations were generated via electroporation. The antiproliferative effects of CTXA were evaluated by MTT\/MTS assays, colony formation, and wound healing assays. Cell cycle distribution and apoptosis were analyzed by flow cytometry. Protein expression of EGFR signaling pathway components (p-EGFR, p-ERK, p-AKT, p-STAT3) and cell cycle regulators (Cyclin D1, CDK4) were examined by Western blotting. Molecular docking and 200 ns molecular dynamics simulations were performed to investigate the stability and binding modes of CTXA to the mutant EGFR kinase domains. Results: The successfully established triple-mutant cell lines exhibited high EGFR expression, IL-3-independent growth, and significant resistance to osimertinib. CTXA inhibited the proliferation of all triple-mutant cell lines in a time- and concentration-dependent manner, with 48 h IC50 values ranging from 0.362 to 2.488 \u03bcM. Mechanistically, CTXA suppressed EGFR autophosphorylation and downregulated downstream p-ERK, p-AKT, and p-STAT3. CTXA induced G1 phase cell cycle arrest by downregulating Cyclin D1 and CDK4, significantly promoted apoptosis, and inhibited cell migration. Molecular docking revealed that while osimertinib binding was blocked by steric hindrance from His-792 or Arg-796, CTXA adapted to the mutated ATP-binding pockets through multiple hydrogen bonds and extensive hydrophobic interactions. Molecular dynamics simulations confirmed the stable binding of CTXA to both mutant EGFR proteins over the 200 ns simulations. Conclusions: This study demonstrates for the first time that the natural compound CTXA possesses antitumor efficacy against EGFR L858R\/T790M\/L792H and L858R\/T790M\/G796R mutants by regulating EGFR-ERK\/AKT\/STAT3 signaling. Our findings position CTXA as a promising lead compound for tackling this challenging form of acquired resistance and highlight the value of natural products in multi-target antitumor drug discovery.<\/jats:p>","DOI":"10.3390\/molecules31091504","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:50:01Z","timestamp":1777618201000},"page":"1504","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cudratricusxanthone A Exhibits Antitumor Activities Against NSCLC Harboring EGFR L792H and G796R Triple Mutations via Regulating EGFR-ERK\/AKT\/STAT3 Signaling"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6345-6713","authenticated-orcid":false,"given":"Yinghao","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"},{"name":"Dabie Mountain Laboratory, College of Tea and Food Science, Xinyang Normal University, Xinyang 464000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiamin","family":"Xian","sequence":"additional","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"},{"name":"School of Medicine and Health, Guangdong Zhaoqing Aviation Vocational College, Zhaoqing 526107, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyi","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingmeng","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Science, Yunnan Agricultural University, Kunming 650201, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruohan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sheng","sequence":"additional","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"},{"name":"College of Science, Yunnan Agricultural University, Kunming 650201, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8677-7165","authenticated-orcid":false,"given":"Peiyuan","family":"Sun","sequence":"additional","affiliation":[{"name":"Key Laboratory of Development and Utilization of Food and Medicinal Resources, Ministry of Education, Yunnan Agricultural University, Kunming 650201, China"},{"name":"College of Science, Yunnan Agricultural University, Kunming 650201, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pandya, P., Al-Qasrawi, D.S., Klinge, S., and Justilien, V. (2024). Extracellular Vesicles in Non-Small Cell Lung Cancer Stemness and Clinical Applications. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1369356"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/14737140.2022.2116004","article-title":"Egfr-Mutant Nsclc: Monitoring the Molecular Evolution of Tumors in 2022","volume":"22","author":"Girard","year":"2022","journal-title":"Expert. Rev. Anticancer Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (Egfr) Exon 20 Insertion Mutations in Lung Cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance Mechanisms to Osimertinib in Egfr-Mutated Non-Small Cell Lung Cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.lungcan.2017.04.003","article-title":"Emergence of Novel and Dominant Acquired Egfr Solvent-Front Mutations at Gly796 (G796s\/R) Together with C797s\/R and L792f\/H Mutations in One Egfr (L858r\/T790m) Nsclc Patient Who Progressed on Osimertinib","volume":"108","author":"Ou","year":"2017","journal-title":"Lung Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2481392","DOI":"10.1080\/14756366.2025.2481392","article-title":"Fourth-Generation Egfr-Tki to Overcome C797s Mutation: Past, Present, and Future","volume":"40","author":"Zhang","year":"2025","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.jtho.2018.05.024","article-title":"Egfr L792h and G796r: Two Novel Mutations Mediating Resistance to the Third-Generation Egfr Tyrosine Kinase Inhibitor Osimertinib","volume":"13","author":"Zhang","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., and Zheng, Q. (2022). Natural Products as Anticancer Agents: Current Status and Future Perspectives. Molecules, 27.","DOI":"10.3390\/molecules27238367"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Yoon, C.S., Kim, D.C., Quang, T.H., Seo, J., Kang, D.G., Lee, H.S., Oh, H., and Kim, Y.C. (2016). A Prenylated Xanthone, Cudratricusxanthone a, Isolated from Cudrania tricuspidata Inhibits Lipopolysaccharide-Induced Neuroinflammation through Inhibition of Nf-\u039ab and P38 Mapk Pathways in Bv2 Microglia. Molecules, 21.","DOI":"10.3390\/molecules21091240"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.intimp.2008.11.008","article-title":"Cudratricusxanthone a from Cudrania tricuspidata Suppresses Pro-Inflammatory Mediators through Expression of Anti-Inflammatory Heme Oxygenase-1 in Raw264.7 Macrophages","volume":"9","author":"Jeong","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/BF02975134","article-title":"Hepatoprotective Constituents of Cudrania tricuspidata","volume":"28","author":"Tian","year":"2005","journal-title":"Arch. Pharm. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"29425","DOI":"10.1038\/s41598-025-14889-x","article-title":"Cudratricusxanthone a Exhibits Antitumor Activity and Enhances Chemosensitivity to Cisplatin against Nsclc Via Targeting Egfr","volume":"15","author":"Sun","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4939-9752-7_2","article-title":"Integrating Molecular Docking and Molecular Dynamics Simulations","volume":"2053","author":"Santos","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.bcp.2021.114643","article-title":"Fighting Tertiary Mutations in Egfr-Driven Lung-Cancers: Current Advances and Future Perspectives in Medicinal Chemistry","volume":"190","author":"Scalvini","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3892\/ijo.2021.5270","article-title":"Mechanisms and Management of 3rd-Generation Egfr-Tki Resistance in Advanced Non-Small Cell Lung Cancer (Review)","volume":"59","author":"He","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-20-0229","article-title":"Ch7233163 Overcomes Osimertinib-Resistant Egfr-Del19\/T790m\/C797s Mutation","volume":"19","author":"Kashima","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","article-title":"Navigating the Landscape of Egfr Tki Resistance in Egfr-Mutant Nsclc\u2014Mechanisms and Evolving Treatment Approaches","volume":"23","author":"Zhao","year":"2026","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/prot.26761","article-title":"L858r\/L718q and L858r\/L792h Mutations of Egfr Inducing Resistance against Osimertinib by Forming Additional Hydrogen Bonds","volume":"93","author":"Imam","year":"2025","journal-title":"Proteins"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming Egfr(T790m) and Egfr(C797s) Resistance with Mutant-Selective Allosteric Inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jtho.2018.04.005","article-title":"Identification of Mutation Accumulation as Resistance Mechanism Emerging in First-Line Osimertinib Treatment","volume":"13","author":"Uchibori","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mce.2017.01.010","article-title":"Stat3 Signaling Mediates Tumour Resistance to Egfr Targeted Therapeutics","volume":"451","author":"Zulkifli","year":"2017","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1158\/1078-0432.CCR-23-3110","article-title":"Anti-Egfr Antibody-Drug Conjugate Carrying an Inhibitor Targeting Cdk Restricts Triple-Negative Breast Cancer Growth","volume":"30","author":"Cheung","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"216968","DOI":"10.1016\/j.canlet.2024.216968","article-title":"Egfr and Her2 Hyper-Activation Mediates Resistance to Endocrine Therapy and Cdk4\/6 Inhibitors in Er+ Breast Cancer","volume":"593","author":"Belli","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"102231","DOI":"10.1016\/j.tranon.2024.102231","article-title":"Cdk4\/6 Inhibitors Promote Parp1 Degradation and Synergize with Parp Inhibitors in Non-Small Cell Lung Cancer","volume":"52","author":"Roggero","year":"2025","journal-title":"Transl. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00018-023-04850-4","article-title":"Sorcin Promotes Migration in Cancer and Regulates the Egf-Dependent Egfr Signaling Pathways","volume":"80","author":"Tito","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"zyae019","DOI":"10.1093\/intbio\/zyae019","article-title":"Multi-Target Therapeutic Modulation with Natural Compounds Towards DNA Repair Mrn-Checkpoint Sensor Genes (Mrn-Csgs) and Oncogenic Mirnas in Breast Cancer Patients: A Clinico-Informatic Study","volume":"16","author":"Singh","year":"2024","journal-title":"Integr. Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e202301081","DOI":"10.1002\/cbdv.202301081","article-title":"Molecular Docking, Pharmacokinetic and Molecular Simulation Analysis of Novel Mono-Carbonyl Curcumin Analogs as L858r\/T790m\/C797s Mutant Egfr Inhibitors","volume":"20","author":"Bhandari","year":"2023","journal-title":"Chem. Biodivers."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"112640","DOI":"10.1016\/j.ejmech.2020.112640","article-title":"Novel Quinazoline-Based Egfr Kinase Inhibitors: A Review Focussing on Sar and Molecular Docking Studies (2015\u20132019)","volume":"204","author":"Bhatia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1021\/acs.jcim.5c00371","article-title":"From Docking and Molecular Dynamics to Experimental Discovery: Exploring the Hydrophobic Landscapes of Heparanase to Design Potent Inhibitors","volume":"65","author":"Abdulsalam","year":"2025","journal-title":"J. Chem. Inf. Model."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"107849","DOI":"10.1016\/j.bioorg.2024.107849","article-title":"Virtual Screening, Molecular Dynamics Simulations, and In Vitro Validation of Egfr Inhibitors as Breast Cancer Therapeutics","volume":"153","author":"Shetty","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Wang, P., Henning, S.M., and Heber, D. (2010). Limitations of Mtt and Mts-Based Assays for Measurement of Antiproliferative Activity of Green Tea Polyphenols. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010202"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2019.01.026","article-title":"Combined Bazedoxifene and Paclitaxel Treatments Inhibit Cell Viability, Cell Migration, Colony Formation, and Tumor Growth and Induce Apoptosis in Breast Cancer","volume":"448","author":"Fu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3892\/ijo.2020.5165","article-title":"Aspirin Inhibits Cholangiocarcinoma Cell Proliferation Via Cell Cycle Arrest in Vitro and in Vivo","volume":"58","author":"Shi","year":"2020","journal-title":"Int. J. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1186\/s12935-021-02330-y","article-title":"Antitumor Effects of the Small Molecule Dmamcl in Neuroblastoma Via Suppressing Aerobic Glycolysis and Targeting Pfkl","volume":"21","author":"Zhang","year":"2021","journal-title":"Cancer Cell Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/gastro\/goaa072","article-title":"Tea Polyphenol Egcg Inhibited Colorectal-Cancer-Cell Proliferation and Migration Via Downregulation of Stat3","volume":"9","author":"Luo","year":"2021","journal-title":"Gastroenterol. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Yu, Y., Zhou, M., Long, X., Yin, S., Hu, G., Yang, X., Jian, W., and Yu, R. (2023). Study on the Mechanism of Action of Colchicine in the Treatment of Coronary Artery Disease Based on Network Pharmacology and Molecular Docking Technology. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1147360"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1016\/j.csbj.2023.09.024","article-title":"Chaperong: A Tool for Automated Gromacs-Based Molecular Dynamics Simulations and Trajectory Analyses","volume":"21","author":"Yekeen","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/9\/1504\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:06:28Z","timestamp":1778501188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/31\/9\/1504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["molecules31091504"],"URL":"https:\/\/doi.org\/10.3390\/molecules31091504","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}